Standard Biotools (LAB) Accumulated Depreciation & Amortization (2011 - 2026)

Standard Biotools (LAB) has 16 years of Accumulated Depreciation & Amortization data on file, last reported at $48.2 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization fell 31.2% year-over-year to $48.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.2 million (down 31.2% YoY) and the FY2025 annual result came in at $47.3 million, up 284.24% from the prior year.
• Accumulated Depreciation & Amortization advanced to $48.2 million in Q1 2026 per LAB's latest filing, from $47.3 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $70.1 million in Q1 2025 and bottomed at $2.8 million in Q4 2022.
• The 5-year median for Accumulated Depreciation & Amortization is $12.9 million (2024), against an average of $23.6 million.
• The widest annual swing landed in 2023, when Accumulated Depreciation & Amortization plunged 86.17%; it then jumped 1249.08% in 2025.
• Tracing LAB's Accumulated Depreciation & Amortization over 5 years: stood at $2.8 million in 2022, then surged by 331.14% to $12.1 million in 2023, then grew by 1.89% to $12.3 million in 2024, then surged by 284.24% to $47.3 million in 2025, then increased by 2.0% to $48.2 million in 2026.
• Per Business Quant, the three latest LAB Accumulated Depreciation & Amortization figures stand at $48.2 million (Q1 2026), $47.3 million (Q4 2025), and $46.7 million (Q3 2025).

Peer Comparison